Почему макролиды эффективны при риносинуситах?

1. Балмасова И.П., Еремина О.Ф., Гультяев М.М. и др. Иммунологические и аллергологические аспекты клинического применения макролидов. Рос. аллергол. журн. 2007; 3: 12–9.
2. Страчунский Л.С., Козлов С.Н. Макролиды в современной клинической практике. Смоленск: Русич, 1998.
3. Фомина И.П. Современные макролиды, особенности действия, значение в лечении бактериальных инфекций. Антибиотики и химиотерапия. 1995; 4: 47–56.
4. Amsden GW. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J Antimicrob Chemother 2005; 55: 10–21.
5. Bosnar M, Kelneric Z, Munic V et al. Cellular Uptake and Efflux of Azithromycin, Erythromycin, Clarithromycin, Telithromycin, and Cethromycin. Antimicrob Agents Chemother 2005; 49: 2372–7.
6. Сervin A, Kalm O, Sandkull P et al. One-year low-dose erythromycin treatment of persistent chronic sinusitis after sinus surgery: clinical outcome and effect on mucociliary parameters and nasal nitric oxide. Otolaryngol Head Neck Surg 2002; 126: 481–9.
7. Cervin A, Wallwork B. Macrolide therapy of chronic rhinosinusitis. Rhinology 2007; 45 (4): 259–67.
8. Craig WA, Gudmundson S. Postantibiotic effect. In: Antibiotic in Laboratory Medicine. Ed.: V.Loran. Baltimore etc., 1996; p. 403–31.
9. Culik O, Eracovic V, Parnham MJ. Anti-inflammatory effects of macrolide antibiotics. Eur J Pharmacol 2001; 429 (1–3): 209–29.
10. Gotfried MN. Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 2004; 125: 52S–61S.
11. Desrosiers MY, Kilty SJ. Treatment alternatives for chronic rhinosinusitis persisting after ESS: what to do when antibiotics, steroids and surgery fail. Rhinology 2008; 46 (1): 3–14.
12. Fokkens W, Lund W, Mullol M. Europian Position Paper on Rhinosinusitis and Nasal polyps 2007. Rhinоlоgy 2007; Suppl. 20.
13. Hashiba M, Baba S. Efficacy of long-term administration of Clarythromycin in the treatment of intractable chronic sinusitis. Acta Otolaryngol 1996; 525 (Suppl.): 73–8.
14. Kanoh S, Rubin BK. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clin Microbiol Rev 2010; 23 (3): 590–615.
15. Labro MT. Cellular ffects of macrolides on leukocyte function. Curr Pharm Design 2004; 10: 3067–80.
16. Lino Y, Sugita K, Toriyama M et al. Erythromycin therapy for otitis media with effusion in sinobronchial syndrome. Arch Otolaryngol Head Neck Surg 1993; 119: 648–51.
17. Nalca Y, Jänsch L, Geffers R et al. Quorum-Sensing Antagonistic Activities of Azithromycin in Pseudomonas aeruginosa PAO1: a Global Approach. Antimicrob Agents Chemother 2006; 50: 1680–8.
18. Rhee CS, Majima Y, Arima S et al. Effects of clarithromycin on rheological properties of nasal mucus in patients with chronic. Ann Otol Rhinol Laryngol 2000; 109: 484–7.
19. Rubin BK, Druce H, Ramires OE et al. Effect of Clarithromycin on nasal mucus properties in healthy sudjects and in patients with purulent rhinitis. Am J Respir Crit Care Med 1997; 155: 2018–23.
20. Wallwork B, Coman W, Mackay-Sim A et al. Effect of Clarithromycin on Nuclear Factor-KB and Transforming Growth Factor-B in Chronic Rhinosinusitis. Laryngoscope 2004; 114: 286–90.
21. Wozniak DJ, Keyser R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest 2004; 125: 62S–69S.

А.В.Варвянская, А.С.Лопатин 

Кафедра болезней уха, горла и носа ГОУ ВПО Первого МГМУ им. И.М.Сеченова Минздравсоцразвития РФ